{"id":1273,"date":"2020-09-16T16:54:26","date_gmt":"2020-09-16T14:54:26","guid":{"rendered":"https:\/\/euroleuk.com\/?page_id=1273"},"modified":"2020-09-16T17:30:05","modified_gmt":"2020-09-16T15:30:05","slug":"jazz-pharmaceuticals-symposium","status":"publish","type":"page","link":"https:\/\/euroleuk.com\/jazz-pharmaceuticals-symposium\/","title":{"rendered":"Jazz Pharmaceuticals Symposium"},"content":{"rendered":"
*High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)<\/strong><\/span><\/p>\n Thursday 29th<\/sup> October, 12:30 \u2013 13:00<\/p>\n This symposium is funded and organised by Jazz Pharmaceuticals. \u00a0<\/em><\/strong>This symposium is intended for healthcare professionals only.<\/em><\/strong><\/p>\n Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse events via their national\u00a0<\/strong>reporting system.<\/strong><\/p>\n\n\n
\n Duration<\/strong><\/td>\n Title<\/strong><\/td>\n Speaker<\/strong><\/td>\n<\/tr>\n \n 2 mins<\/td>\n Welcome and Introduction<\/td>\n Prof Alessandro Isidori, Italy<\/td>\n<\/tr>\n \n 24 mins<\/td>\n Laying the Foundation for Long Term Remission in High-Risk AML*<\/td>\n Dr Donal McLornan, UK<\/td>\n<\/tr>\n \n 4 mins<\/td>\n Summary and Close<\/td>\n Prof Alessandro Isidor, Italy<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\nThis symposium will contain promotional content and prescribing information will be shown at the end of each presentation and at the end of the symposium.<\/em><\/strong><\/p>\n\n\n
\n \n